2026-06-22

Cocoa bull 10.7% vs prior close ($4,143.00 → $4,588.00)

OSINT: Bitcoin Surpasses $65K as US‑Iran Talks Calm Tensions

OSINT: Ukraine hits Russian Voronezh semiconductor plant tied to Iskander missiles

OSINT: Russian Poll Forecast Raises Market Caution

OSINT: US Air Force and Navy Conduct Surveillance Flights Over Strait of Hormuz

CFTC SILVER speculators at extreme short: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OIL RSI 22.2 - oversold (crossed below 30)

OSINT: Explosions in Crimea Force Closure of Kerch Bridge

Cotton bull 4.7% vs prior close ($76.05 → $79.61)

Cocoa volume spike - 2.1× the 20-day average (30,960 vs 15,060 avg)

OSINT: Ukrainian drones strike southern Russia and Crimea overnight

OSINT: Ukrainian Drone Strikes Trigger Fuel Rationing Across Russian Regions

OSINT: Iran Threatens Closure of Strait of Hormuz, Heightening Tensions

OSINT: Iranian Geopolitical Tensions Escalate, Raising Market Concerns

OIL RSI 21.8 - oversold (crossed below 30)

SPYx/USDC has $77.1M 24h volume on $1185K liquidity (65x turnover): thin market, elevated slippage

SOL open interest -73.1% - OI collapse

BTC open interest -41.4% - OI collapse

ETH open interest -67.7% - OI collapse

SPYx/USDC has $63.2M 24h volume on $982K liquidity (64x turnover): thin market, elevated slippage

SPYx/USDC has $63.8M 24h volume on $795K liquidity (80x turnover): thin market, elevated slippage

SPYx/USDC has $69.8M 24h volume on $1029K liquidity (68x turnover): thin market, elevated slippage

BTC open interest -38.3% - OI collapse

SOL open interest -63.6% - OI collapse

ETH open interest +203.2% - OI surge

SPYx/USDC has $73.0M 24h volume on $1431K liquidity (51x turnover): thin market, elevated slippage

SPYx/USDC has $73.2M 24h volume on $1033K liquidity (71x turnover): thin market, elevated slippage

SPYx/USDC has $75.6M 24h volume on $1312K liquidity (58x turnover): thin market, elevated slippage

SPYx/USDC has $77.8M 24h volume on $959K liquidity (81x turnover): thin market, elevated slippage

SPYx/USDC has $78.0M 24h volume on $1225K liquidity (64x turnover): thin market, elevated slippage

BTC open interest +234.2% - OI surge

SOL open interest -72.9% - OI collapse

ETH open interest -67.7% - OI collapse

SPYx/USDC has $79.8M 24h volume on $994K liquidity (80x turnover): thin market, elevated slippage

SPYx/USDC has $81.2M 24h volume on $1258K liquidity (65x turnover): thin market, elevated slippage

SPYx/USDC has $80.3M 24h volume on $1009K liquidity (80x turnover): thin market, elevated slippage

SPYx/USDC has $82.1M 24h volume on $796K liquidity (103x turnover): thin market, elevated slippage

SPYx/USDC has $82.2M 24h volume on $1066K liquidity (77x turnover): thin market, elevated slippage

SPYx/USDC has $85.5M 24h volume on $774K liquidity (111x turnover): thin market, elevated slippage

SPYx/USDC has $66.3M 24h volume on $648K liquidity (102x turnover): thin market, elevated slippage

SPYx/USDC has $86.4M 24h volume on $1000K liquidity (86x turnover): thin market, elevated slippage

SPYx/USDC has $86.6M 24h volume on $1080K liquidity (80x turnover): thin market, elevated slippage

SPYx/USDC has $67.0M 24h volume on $654K liquidity (102x turnover): thin market, elevated slippage

ETH open interest -68.4% - OI collapse

BTC open interest -39.8% - OI collapse

SOL open interest -72.8% - OI collapse

SOL DEX volume/liquidity ratio elevated (3.32x): on-chain trade volume 3.32x liquidity

OSINT: Solana Foundation launches open data platform for ecosystem metrics

OSINT: Bitcoin Spot ETFs See 6th Week of $226.8M Outflows, Altcoins Attract Inflows

OSINT: Solana token $STRC drops ~2% after tweet

OSINT: Trump remarks spark calm in US markets

OSINT: Solana ecosystem sees funding, RWA lead, token launch and Jupiter Predict ATH

SOL DEX volume/liquidity ratio elevated (4.11x): on-chain trade volume 4.11x liquidity

OSINT: Securitize Calls tZERO Patent Claims Meritless, Prepares Legal Challenge

china_us_west shipping +13.3% - potential inflation signal

china_us_west shipping +13.3% - potential inflation signal

china_us_west shipping +13.3% - potential inflation signal

china_us_west shipping +13.3% - potential inflation signal

OSINT: Explosions in Crimea Force Closure of Kerch Bridge

OSINT: Explosions in Crimea Force Closure of Kerch Bridge

OSINT: Ukrainian drones strike southern Russia and Crimea overnight

OSINT: Ukrainian drones strike southern Russia and Crimea overnight

OSINT: Trump remarks spark calm in US markets

OSINT: Iran Threatens Closure of Strait of Hormuz, Heightening Tensions

OSINT: US AF2 and SAM‑954 aircraft land at RAF Mildenhall

OSINT: Iranian Geopolitical Tensions Escalate, Raising Market Concerns

OSINT: Iranian Geopolitical Tensions Escalate, Raising Market Concerns

Phase 3 trial terminated early - JOHNSON CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Follo

Phase 3 trial terminated early - JOHNSON To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patien

Phase 3 trial terminated early - ELI A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Phase 3 trial terminated early - BRISTOL Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Phase 3 trial terminated early - AMGEN Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiv

Phase 3 trial terminated early - AMGEN Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovas

Phase 3 trial terminated early - AMGEN Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)

Phase 3 trial terminated early - INCYTE A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythemat

Phase 3 trial terminated early - INCYTE Study of the Efficacy and Safety of Parsaclisib in Participants With Primary War

Phase 3 trial terminated early - INCYTE Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-A

Phase 3 trial terminated early - Medtronic Comparison of Absorbable Sutures in Perineal Laceration Repair

Phase 3 trial terminated early - Medtronic Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty

Phase 3 trial terminated early - Medtronic HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study

Phase 3 trial terminated early - AbbVie Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazin

Phase 3 trial terminated early - AbbVie A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking

Phase 3 trial terminated early - Merck Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With I

Phase 3 trial terminated early - Merck Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patient

Phase 3 trial terminated early - Merck Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic

Phase 3 trial terminated early - PFIZER Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended R

Phase 3 trial terminated early - PFIZER Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The T

Phase 3 trial terminated early - PFIZER Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELI

Phase 3 trial terminated early - PFIZER Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Phase 3 trial terminated early - PFIZER One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome

Phase 3 trial terminated early - ABBOTT A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatmen

Phase 3 trial terminated early - GILEAD Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to C

Phase 3 trial terminated early - GILEAD Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Act

Phase 3 trial terminated early - GILEAD Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With H

Phase 3 trial terminated early - GILEAD Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of

SHOPIFY INC. search volume spiked +60 pts - unusual interest

OSINT: Google invests $75M in A24 for AI film partnership

CITIGROUP INC search volume spiked +100 pts - unusual interest

EXELON CORP search volume spiked +100 pts - unusual interest

OSINT: Trump remarks spark calm in US markets

SOUTHERN CO search volume spiked +31 pts - unusual interest

OSINT: Nvidia says AI's water challenge is largely solved

ILLINOIS TOOL WORKS INC search volume spiked +100 pts - unusual interest

OSINT: Solana ecosystem sees funding, RWA lead, token launch and Jupiter Predict ATH

Tri Pointe Homes, Inc. search volume spiked +100 pts - unusual interest

PROGRESSIVE CORP/OH/ search volume spiked +50 pts - unusual interest

GAP INC search volume spiked +57 pts - unusual interest

OSINT: Securitize Calls tZERO Patent Claims Meritless, Prepares Legal Challenge

EXELON CORP search volume spiked +100 pts - unusual interest

Q2-2025: Missed consensus by 13.9% - EPS $-0.23 vs $-0.202 estimate

Q3-2025: Missed consensus by 122.2% - EPS $-0.34 vs $-0.153 estimate

Q3-2026: Beat consensus by 56.9% - EPS $0.08 vs $0.051 estimate

Q2-2025: Missed consensus by 50.3% - EPS $-0.23 vs $-0.153 estimate

Q3-2025: Beat consensus by 217.6% - EPS $0.18 vs $-0.153 estimate

Q4-2024: Beat consensus by 21.6% - EPS $-1.6 vs $-2.04 estimate

Q2-2024: Missed consensus by 37.3% - EPS $-2.8 vs $-2.04 estimate

Q3-2024: Beat consensus by 18.3% - EPS $-2 vs $-2.448 estimate

Q2-2026: Missed consensus by 133.8% - EPS $-0.31 vs $-0.1326 estimate

Q1-2026: Beat consensus by 26.5% - EPS $-0.15 vs $-0.204 estimate

Q1-2026: Beat consensus by 7.2% - EPS $9.71 vs $9.057 estimate

Q1-2027: Beat consensus by 11.4% - EPS $1.3 vs $1.167 estimate

Q1-2026: Missed consensus by 718.6% - EPS $-1.67 vs $-0.204 estimate

Q2-2026: Missed consensus by 5664.7% - EPS $-2.94 vs $-0.051 estimate

Q3-2026: Missed consensus by 718.6% - EPS $-1.67 vs $-0.204 estimate

Q4-2025: Missed consensus by 5664.7% - EPS $-2.94 vs $-0.051 estimate

Q4-2025: Beat consensus by 21.9% - EPS $2.4 vs $1.9686 estimate

Q2-2025: Missed consensus by 19.8% - EPS $1.5 vs $1.87 estimate

Q1-2026: Beat consensus by 19.3% - EPS $1.6 vs $1.3413 estimate

Q3-2025: Beat consensus by 69.7% - EPS $3 vs $1.768 estimate

Q2-2025: Missed consensus by 7.3% - EPS $2.07 vs $2.232 estimate

Q4-2025: Missed consensus by 267.3% - EPS $-1.2341 vs $-0.336 estimate

Q1-2026: Missed consensus by 6.7% - EPS $1.12 vs $1.2 estimate

Q2-2025: Beat consensus by 31.4% - EPS $-0.07 vs $-0.102 estimate

Q4-2026: Missed consensus by 40.2% - EPS $-1.43 vs $-1.02 estimate

Q2-2026: Beat consensus by 49.0% - EPS $-0.26 vs $-0.51 estimate

Q2-2025: Beat consensus by 6.4% - EPS $0.4 vs $0.376 estimate

Q2-2026: Beat consensus by 55.4% - EPS $0.157 vs $0.101 estimate

Q4-2025: Beat consensus by 55.8% - EPS $1.51 vs $0.969 estimate

Q1-2026: Missed consensus by 88.1% - EPS $-0.19 vs $-0.101 estimate

Q3-2025: Beat consensus by 9.8% - EPS $0.73 vs $0.665 estimate

Q1-2027: Beat consensus by 15.8% - EPS $1.71 vs $1.477 estimate

Q4-2026: Beat consensus by 12.1% - EPS $2.44 vs $2.177 estimate

Q4-2011: Missed consensus by 46.4% - EPS $0.141 vs $0.263 estimate

Q4-2012: Missed consensus by 293.0% - EPS $-0.2992 vs $0.155 estimate

Q1-2024: Beat consensus by 16.2% - EPS $-7700 vs $-9191 estimate

Q2-2024: Beat consensus by 50.5% - EPS $-2800 vs $-5656 estimate

Q3-2024: Beat consensus by 67.2% - EPS $-2.32 vs $-7.07 estimate

Q1-2026: Beat consensus by 31.4% - EPS $-0.07 vs $-0.102 estimate

Q4-2025: Missed consensus by 31.1% - EPS $-0.13371 vs $-0.102 estimate

Q3-2025: Missed consensus by 37.3% - EPS $-0.07 vs $-0.051 estimate

Q4-2024: Missed consensus by 390.2% - EPS $-0.5 vs $-0.102 estimate

Q1-2009: Missed consensus by 60.4% - EPS $0.16989 vs $0.429 estimate

Q1-2026: Beat consensus by 26.3% - EPS $-0.28 vs $-0.38 estimate

Q3-2000: Beat consensus by 38.6% - EPS $0.7 vs $0.505 estimate

Q1-2026: Missed consensus by 138.5% - EPS $-0.02 vs $0.052 estimate

Q1-2026: Missed consensus by 209.4% - EPS $-1.42 vs $-0.459 estimate

Q3-2025: Beat consensus by 40.4% - EPS $-0.79 vs $-1.326 estimate

Q3-2022: Beat consensus by 32.6% - EPS $-1.1 vs $-1.632 estimate

Q2-2022: Beat consensus by 57.1% - EPS $-0.7 vs $-1.632 estimate

Q2-2023: Missed consensus by 7.3% - EPS $1.549 vs $1.671 estimate

Q1-2026: Missed consensus by 13.8% - EPS $-0.61 vs $-0.536 estimate

Q1-2026: Beat consensus by 35.6% - EPS $0.137 vs $0.101 estimate

Q2-2025: Missed consensus by 68.3% - EPS $-0.17 vs $-0.101 estimate

Q3-2019: Missed consensus by 782.4% - EPS $-4.5 vs $-0.51 estimate

Q2-2019: Missed consensus by 369.6% - EPS $-5.5 vs $2.04 estimate

Q1-2019: Missed consensus by 263.4% - EPS $-5 vs $3.06 estimate

Q4-2026: Beat consensus by 22.6% - EPS $55.153 vs $44.998 estimate

Q4-2025: Beat consensus by 43.7% - EPS $-0.08 vs $-0.142 estimate

Q1-2025: Beat consensus by 255.3% - EPS $0.07919999999999999 vs $-0.051 estimate

Q4-2025: Missed consensus by 25.0% - EPS $-0.42 vs $-0.336 estimate

Q2-2025: Beat consensus by 22.2% - EPS $0.81 vs $0.663 estimate

Q2-2026: Beat consensus by 60.8% - EPS $-0.02 vs $-0.051 estimate

Q4-2025: Beat consensus by 12.0% - EPS $1.58 vs $1.411 estimate

Q3-2025: Beat consensus by 21.6% - EPS $-0.16 vs $-0.204 estimate

Q1-2026: Beat consensus by 55.3% - EPS $-0.19 vs $-0.425 estimate

Q4-2025: Missed consensus by 6.1% - EPS $-0.47 vs $-0.443 estimate

Q2-2022: Missed consensus by 60.8% - EPS $0.02 vs $0.051 estimate

Q1-2022: Missed consensus by 41.2% - EPS $0.03 vs $0.051 estimate

Q3-2010: Beat consensus by 7.0% - EPS $240 vs $224.4 estimate

Q2-2010: Beat consensus by 17.6% - EPS $240 vs $204 estimate

Q4-2025: Beat consensus by 9.1% - EPS $3.11 vs $2.851 estimate

Q2-2023: Missed consensus by 92.4% - EPS $-7.95 vs $-4.131 estimate

Q3-2024: Missed consensus by 34.6% - EPS $4 vs $6.12 estimate

Q4-2024: Missed consensus by 1717.6% - EPS $-66 vs $4.08 estimate

Q1-2026: Missed consensus by 36.9% - EPS $0.44 vs $0.697 estimate

Q1-2026: Missed consensus by 139.5% - EPS $-0.03 vs $0.076 estimate

Q3-2025: Beat consensus by 20.2% - EPS $0.53 vs $0.441 estimate

Q2-2025: Beat consensus by 6.8% - EPS $0.41 vs $0.3838 estimate

Q2-2025: Missed consensus by 23.0% - EPS $-1.38 vs $-1.122 estimate

Q1-2026: Missed consensus by 9.1% - EPS $2.72 vs $2.992 estimate

Q2-2026: Beat consensus by 1547.1% - EPS $0.84 vs $0.051 estimate

Q4-2025: Beat consensus by 60.8% - EPS $-0.02 vs $-0.051 estimate

OSINT: Explosions in Crimea Force Closure of Kerch Bridge

OSINT: Ukrainian drones strike southern Russia and Crimea overnight

OSINT: Ukrainian Drone Strikes Trigger Fuel Rationing Across Russian Regions

OSINT: Trump remarks spark calm in US markets

OSINT: Iran Threatens Closure of Strait of Hormuz, Heightening Tensions

OSINT: Iranian Geopolitical Tensions Escalate, Raising Market Concerns